lmx1b
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">lmx1b</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>LMX1B</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>LIM Homeobox Transcription Factor 1 Beta</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q33.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>4010</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>602575</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>O43823</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000136944</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>372 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~41 kDa</td>
</tr>
<tr>
<td class="label">Co-factor</td>
<td>Interaction Domain</td>
</tr>
<tr>
<td class="label">CLIM1/Ldb1</td>
<td>LIM domains</td>
</tr>
<tr>
<td class="label">NLI</td>
<td>LIM domains</td>
</tr>
<tr>
<td class="label">p300/CBP</td>
<td>C-terminal domain</td>
</tr>
<tr>
<td class="label">HDAC1/2</td>
<td>C-terminal domain</td>
</tr>
<tr>
<td class="label">LMO1/2</td>
<td>LIM domains</td>
</tr>
<tr>
<td class="label">Signal</td>
<td>Effect on LMX1B</td>
</tr>
<tr>
<td class="label">Oxidative stress</td>
<td>Upregulation</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>Downregulation</td>
</tr>
<tr>
<td class="label">Mitochondrial toxins</td>
<td>Altered localization</td>
</tr>
<tr>
<td class="label">Neuronal activity</td>
<td>Modulation</td>
</tr>
<tr>
<td class="label">Vector</td>
<td>Tropism</td>
</tr>
<tr>
<td class="label">AAV2</td>
<td>Neurons</td>
</tr>
<tr>
<td class="label">AAV9</td>
<td>CNS-wide</td>
</tr>
<tr>
<td class="label">AAV-PHP.B</td>
<td>CNS-wide</td>
</tr>
<tr>
<td class="label">Lentivirus</td>
<td>Neurons</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
The LMX1B (LIM Homeobox Transcription Factor 1 Beta) gene encodes a critical transcription factor required for the proper development and maintenance of dopaminergic neurons in the midbrain. LMX1B plays essential roles in neural development, limb patterning, and has been implicated in Parkinson's disease pathogenesis through its regulation of genes involved in neuronal survival, mitochondrial function, and protein homeostasis[@smidt2002][@dresser2000]. This gene represents a fascinating intersection between developmental biology and neurodegenerative disease research, as its dysfunction reveals both congenital syndromes and late-onset neurological disorders.
Gene and Protein Structure
Genomic Organization
The LMX1B gene is located on chromosome 9q33.3 and spans approximately 15 kilobases of genomic DNA. It consists of 5 exons encoding a protein of 372 amino acids with a molecular weight of approximately 41 kDa. The gene is transcribed from a promoter region that contains multiple transcription factor binding sites, allowing for precise spatiotemporal regulation of its expression during development and in adult tissues.
Protein Domain Architecture
The LMX1B protein contains several distinct functional domains that mediate its diverse biological functions:
N-terminal LIM Domains: Two LIM domains (LIN-11, Islet-1, MEC-3) located at the N-terminus (amino acids 1-60 and 61-120) that mediate protein-protein interactions with other transcription factors and co-factors
Homeodomain: A DNA-binding homeodomain (amino acids 165-224) that recognizes and binds to specific DNA sequences
C-terminal Transcriptional Activation Domain: A regulatory region that interacts with transcriptional co-activators and co-repressorsMermaid diagram (expand to render)
Biological Functions
Transcriptional Regulation in Dopaminergic Neuron Development
LMX1B serves as a master regulator of dopaminergic neuron specification during embryonic development. Its expression in the midbrain floor plate is essential for the activation of a genetic program that determines dopaminergic cell fate. LMX1B directly regulates the expression of key dopaminergic markers including[@maxwell2011][@prakash2013]:
- TH (Tyrosine Hydroxylase) — the rate-limiting enzyme in dopamine synthesis
- DAT (Dopamine Transporter, SLC6A3) — responsible for dopamine reuptake
- AADC (Aromatic L-Amino Acid Decarboxylase, DDC) — converts L-DOPA to dopamine
- VMAT2 (Vesicular Monoamine Transporter 2, SLC18A2) — packages dopamine into synaptic vesicles
- PITX3 — another critical transcription factor for dopaminergic neuron survival
- NR4A2 (NURR1) — essential for dopaminergic neuron maintenance
Protein Structure and Mechanism
The LMX1B protein functions as both a transcriptional activator and repressor, depending on its interacting partners. It can recruit histone acetyltransferases (such as p300/CBP) to activate target genes, or interact with co-repressors to suppress transcription. This dual functionality allows precise control of gene expression programs in response to developmental signals and environmental cues.
Role in Mitochondrial Function
Recent research has demonstrated that LMX1B regulates genes involved in mitochondrial dynamics, biogenesis, and function[@vincenz2023]. This includes:
- PGC-1α (PPARGC1A) — master regulator of mitochondrial biogenesis
- TFAM — mitochondrial transcription factor A
- Complex I subunits — components of the electron transport chain
- Mitochondrial dynamics regulators — DRP1 (DNM1L), MFN1/2, OPA1
Dysregulation of these genes contributes to mitochondrial dysfunction, a hallmark of Parkinson's disease pathology.
Protein Homeostasis Regulation
LMX1B also influences the autophagy-lysosome and ubiquitin-proteasome systems, which are critical for clearing misfolded proteins and damaged organelles[@song2018]. It regulates:
- LC3 (MAP1LC3A) and ATG proteins — key components of the autophagy machinery
- SQSTM1/p62 — a receptor for selective autophagy
- Ubiquitin-conjugating enzymes — components of the ubiquitin-proteasome system
This function is particularly relevant to Parkinson's disease, where alpha-synuclein aggregation and impaired protein clearance are central pathological features.
Molecular Mechanisms
Transcriptional Regulation Network
LMX1B operates within an intricate transcriptional network that governs dopaminergic neuron development and maintenance. The protein functions as both a transcriptional activator and repressor, depending on its interacting partners and the cellular context. This versatility allows LMX1B to coordinate complex gene expression programs essential for neuronal survival and function.
The transcriptional activity of LMX1B is modulated by several key mechanisms:
1. Protein-Protein Interactions
LMX1B interacts with various co-factors to modulate its transcriptional activity:
- p300/CBP: Histone acetyltransferases that enhance target gene transcription
- LDB1 (LIM Domain Binding 1): Essential co-factor for LIM homeodomain proteins
- CLIM/NLI: Co-factors that enhance LMX1B transcriptional activity
2. DNA Binding SpecificityLMX1B binds to consensus DNA sequences through its homeodomain:
- Recognition motif: TAAATNA (where N is any nucleotide)
- Preference for AT-rich regions in promoter/enhancer elements
- Ability to bind both monomeric and dimeric sites
3. Chromatin RemodelingLMX1B influences chromatin structure to facilitate or inhibit gene expression:
- Recruitment of histone modifiers
- Modulation of nucleosome positioning
- Regulation of enhancer activity
Signaling Pathways Modulating LMX1B
Several signaling pathways regulate LMX1B expression and activity:
Wnt Signaling
The Wnt pathway directly influences Lmx1b expression during development:
- Wnt ligands activate beta-catenin, which can modulate Lmx1b transcription
- Cross-talk between Wnt and LMX1B in midbrain patterning
- Implications for dopaminergic neuron development
Sonic Hedgehog (Shh) SignalingShh signaling is crucial for midbrain floor plate specification:
- Shh regulates Lmx1b expression in the ventral neural tube
- Gradient-dependent effects on dopaminergic neuron specification
- Interaction with other floor plate transcription factors
FGF SignalingFibroblast growth factor signaling modulates Lmx1b:
- FGF8 promotes Lmx1b expression in the midbrain
- Maintains dopaminergic progenitor proliferation
- Coordinates with other signals for proper patterning
Disease Associations
Parkinson's Disease
LMX1B has been increasingly recognized as a susceptibility gene for Parkinson's disease[@singleton2013][@nalls2014][@chang2017]. While not a causative mutation in the majority of cases, LMX1B polymorphisms and expression changes have been associated with:
- Reduced dopaminergic neuron survival — decreased LMX1B expression correlates with increased vulnerability of substantia nigra neurons
- Mitochondrial dysfunction — impaired regulation of mitochondrial genes leads to energy deficit and increased oxidative stress
- Protein aggregation propensity — dysregulated autophagy leads to accumulation of alpha-synuclein and other protein aggregates
- Neuroinflammation — altered immune response gene regulation contributes to chronic neuroinflammation
Genome-wide association studies (GWAS) have identified LMX1B variants as suggesting susceptibility loci for sporadic Parkinson's disease, though the effect sizes are modest. The identification of LMX1B as a Parkinson's disease susceptibility gene provides insight into the molecular pathways that regulate dopaminergic neuron survival and highlights the importance of transcription factor regulation in neurodegeneration.
Nail-Patella Syndrome
Classical LMX1B mutations cause nail-patella syndrome (NPS), characterized by[@dunham2012]:
- Dysplastic nails — ridged, discolored, or absent nails
- Patellar hypoplasia/absence — small or missing kneecaps
- Iliac horns — characteristic bony projections from the iliac bones
- Glaucoma risk — increased risk of open-angle glaucoma
- Renal disease — proteinuria and renal failure in some cases
Interestingly, some nail-patella syndrome patients show movement disorders, suggesting broader neurological effects of LMX1B dysfunction. This observation has prompted investigations into the role of LMX1B in the central nervous system beyond its well-characterized role in limb development.
Potential Therapeutic Implications
Given LMX1B's role in dopaminergic neuron survival, therapeutic strategies targeting LMX1B signaling are under investigation[@le2020]:
Gene therapy approaches — delivering functional LMX1B to enhance dopaminergic neuron resilience
Small molecule modulators — developing compounds that enhance LMX1B transcriptional activity
Downstream targeting — focusing on genes regulated by LMX1B (TH, DAT, PGC-1α) rather than LMX1B itself
Protein stabilization — preventing LMX1B degradation to maintain dopaminergic neuron functionExpression Patterns
Brain Region-Specific Expression
LMX1B is expressed throughout the brain, with particularly high levels in[@jellinger2023]:
- Substantia nigra pars compacta — the primary site of dopaminergic neuron cell bodies
- Ventral tegmental area — dopaminergic neurons projecting to limbic structures
- Hippocampus — particularly CA1 and CA3 regions
- Cortex — layer 5 pyramidal neurons
- Spinal cord — motor neurons and interneurons
Developmental Expression Pattern
During development, LMX1B expression begins around embryonic day 10.5 in the midbrain floor plate and persists throughout life in mature dopaminergic neurons. This sustained expression suggests ongoing functions beyond development, including maintenance and survival of adult neurons.
Regulation of LMX1B Expression
LMX1B expression is regulated by:
- Transcription factors — including OTX2, PITX3, and FOXA2
- Signaling pathways — Wnt, Shh, and FGF signaling modulate Lmx1b expression
- Epigenetic mechanisms — DNA methylation and histone modifications influence LMX1B transcription
- Environmental factors — oxidative stress, neuroinflammation, and aging affect LMX1B levels
Interaction Network
Directly Interacting Proteins
- PITX3 — another dopaminergic transcription factor that cooperates with LMX1B
- OTX2 — midbrain patterning factor that regulates LMX1B
- MSX1/2 — homeodomain proteins that interact with LIM domains
- LDB1/CLIM — co-factors that enhance LMX1B transcriptional activity
- p300/CBP — histone acetyltransferases for transcriptional activation
Downstream Target Genes
- TH — tyrosine hydroxylase (dopamine synthesis)
- DAT (SLC6A3) — dopamine transporter
- VMAT2 (SLC18A2) — vesicular monoamine transporter
- AADC (DDC) — aromatic L-amino acid decarboxylase
- PGC-1α (PPARGC1A) — mitochondrial biogenesis regulator
- NR4A2 (NURR1) — dopaminergic neuron maintenance
Pathway Membership
- Dopaminergic neuron development pathway
- Parkinson's disease mechanism pathway
- Transcription factor regulatory network
- Mitochondrial function pathway
- Autophagy and protein homeostasis pathway
Therapeutic Target Rationale
Rationale for Targeting LMX1B
LMX1B represents an attractive therapeutic target for Parkinson's disease due to its central role in dopaminergic neuron survival. Several strategies are being explored:
1. Gene Therapy Approaches
- AAV-mediated delivery of functional LMX1B
- CRISPR-based activation of endogenous LMX1B expression
- Small molecule transcriptional activators
2. Downstream Modulation
- Targeting genes regulated by LMX1B (TH, DAT, AADC)
- Enhancing mitochondrial function through PGC-1α activation
- Promoting autophagy through ATG gene activation
3. Combination Strategies
- LMX1B modulation with neurotrophic factors
- Synergistic effects with dopaminergic medications
- Protection against environmental toxins
Challenges
- Delivering therapeutic agents to the substantia nigra
- Balancing transcriptional activation to avoid oncogenic effects
- Ensuring cell-type specificity
- Overcoming the blood-brain barrier
Animal Models
Knockout Mice
Lmxb1 knockout mice demonstrate:
- Embryonic lethality in complete knockouts
- Defects in limb development (mirroring nail-patella syndrome)
- Loss of dopaminergic neurons in the substantia nigra
- Motor deficits reminiscent of Parkinson's disease
Conditional Knockouts
Neuron-specific Lmx1b deletion shows:
- Progressive loss of dopaminergic neurons
- Motor dysfunction
- Mitochondrial abnormalities
- Alpha-synuclein pathology
Transgenic Models
Transgenic mice overexpressing Lmx1b demonstrate:
- Enhanced dopaminergic neuron survival
- Resistance to neurotoxic insults
- Improved mitochondrial function
Research Directions
Key Unanswered Questions
What are the precise molecular mechanisms by which LMX1B variants contribute to Parkinson's disease risk?
Can LMX1B expression be safely modulated in adult neurons for therapeutic purposes?
What determines the cell-type specificity of LMX1B's effects?
Are there biomarkers that can predict response to LMX1B-targeted therapies?Emerging Research Areas
- Induced pluripotent stem cell (iPSC) models of LMX1B variants
- Single-cell transcriptomics of dopaminergic neurons
- Structure-based drug design for LMX1B modulators
- Gene editing approaches for correcting pathogenic variants
Cross-Links
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-psp)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [Dopamine Metabolism](/mechanisms/pd-dopamine-metabolism)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
- [Alpha-Synuclein Pathology](/mechanisms/synucleinopathies)
- [Autophagy Dysfunction](/mechanisms/autophagy-bioactive-compounds)
- [PITX3](/genes/pitx3) — cooperating transcription factor
- [TH](/genes/th) — tyrosine hydroxylase
- [NR4A2 (NURR1](/genes/nr4a2) — dopaminergic neuron maintenance
- [SOX6](/genes/sox6) — dopaminergic development
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Dopamine Metabolism](/mechanisms/pd-dopamine-metabolism)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
Clinical Significance
Diagnostic Implications
LMX1B testing is clinically available for:
- Nail-patella syndrome confirmation: Genetic testing for pathogenic variants
- Parkinson's disease risk assessment: GWAS-based risk scoring
- Differential diagnosis: Distinguishing from similar phenotypes
- Dopaminergic neuron health monitoring: Expression levels as surrogate marker
Research and Therapeutic Outlook
Current research directions include:
Gene therapy development: AAV-mediated LMX1B delivery to substantia nigra
Small molecule activators: Compounds that enhance LMX1B transcriptional activity
Cell replacement therapy: Dopaminergic neurons derived from stem cells with LMX1B overexpression
Biomarker development: LMX1B expression as a biomarker for dopaminergic neuron health
Combination approaches: LMX1B with other dopaminergic survival factorsMolecular Mechanisms
LMX1B functions within transcriptional complexes that include:
Downstream Target Gene Network
LMX1B regulates a comprehensive gene network in dopaminergic neurons:
Dopamine biosynthesis and transport:
- TH (tyrosine hydroxylase)
- DDC (AADC)
- SLC6A3 (DAT)
- SLC18A2 (VMAT2)
- SLC18A1 (VMAT1)
Neuronal survival:
- NRTN (neurturin)
- GDNF (glial cell line-derived neurotrophic factor)
- BCL2 family members
Mitochondrial function:
- PPARGC1A (PGC-1α)
- TFAM
- NRF1, NRF2
- Complex I subunits (ND subunits)
Protein homeostasis:
- MAP1LC3A/B (LC3)
- SQSTM1 (p62)
- UBQLN1, UBQLN2
- LAMP1, LAMP2
Animal Models
Knockout Mice
Lmx1b knockout mice demonstrate:
- Embryonic lethality: Complete knockout is embryonic lethal around E12.5-14.5
- Dopaminergic neuron loss: Conditional knockouts show loss of TH-positive neurons
- Limb malformations: Similar to nail-patella syndrome
- Eye defects: Coloboma and other ocular abnormalities
Conditional Knockouts
Neuron-specific Lmx1b deletion reveals:
- Progressive dopaminergic neuron loss in substantia nigra
- Reduced striatal dopamine levels
- Motor behavioral deficits
- Age-related degeneration
- Mitochondrial dysfunction
Transgenic Models
Lmx1b overexpression studies show:
- Enhanced dopaminergic neuron survival
- Increased TH expression
- Protection against MPTP toxicity
- Improved mitochondrial function
- Enhanced autophagy
Knock-in Models
Disease-associated Lmx1b variants:
- Generate models with hypomorphic function
- Demonstrate partial penetrance
- Model susceptibility factors
- Show gene-environment interactions
Signaling Pathways
Developmental Pathways
During development, LMX1B is regulated by:
Wnt/β-catenin pathway: Activates Lmx1b expression in floor plate
Shh (Sonic Hedgehog): Establishes ventral midbrain patterning
FGF8: Specifies midbrain-hindbrain boundary
BMP signaling: Patterns dorsoventral axisMature Neuron Signaling
In adult neurons, LMX1B responds to:
Therapeutic Development
Gene Therapy Vectors
Small Molecule Approaches
Epigenetic modulators: HDAC inhibitors that enhance LMX1B expression
Nuclear receptor agonists: PPAR agonists that increase PGC-1α (LMX1B target)
Neurotrophic factors: GDNF family ligands that preserve LMX1B-expressing neurons
Antioxidants: N-acetylcysteine, coenzyme Q10 that reduce oxidative stressCell Therapy
- Stem cell-derived dopaminergic neurons: Overexpress LMX1B for enhanced survival
- Gene correction: Edit LMX1B variants in patient-derived cells
- Combination therapy: LMX1B with TH, AADC for complete dopamine pathway
Biomarker Potential
Diagnostic Biomarkers
LMX1B as a biomarker:
Expression levels: Reduced LMX1B in PD patient brain tissue
Genetic variants: Risk alleles identified in GWAS
Protein levels: Measurable in CSF (emerging)
Activity markers: Target gene expression as functional readoutDisease Progression
- LMX1B expression correlates with disease stage
- Decline predicts motor symptom progression
- Responds to dopaminergic therapy
Cross-Links
- [PITX3](/genes/pitx3) — cooperating transcription factor
- [TH](/genes/th) — tyrosine hydroxylase
- [NR4A2 (NURR1)](/genes/nr4a2) — dopaminergic neuron maintenance
- [SOX6](/genes/sox6) — dopaminergic development
- [OTX2](/genes/otx2) — midbrain patterning
- [FOXA2](/genes/foxa2) — floor plate specification
- [PAX2](/genes/pax2) — midbrain-hindbrain boundary
- [LMX1A](/genes/lmx1a) — paralog with similar function
- [Alpha-synuclein](/proteins/alpha-synuclein)
- [Parkin](/proteins/parkin-protein)
- [PGC-1α](/proteins/pgc1-alpha-protein)
- [TH protein](/proteins/tyrosine-hydroxylase-protein)
- [Dopamine Metabolism](/mechanisms/pd-dopamine-metabolism)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
- [Alpha-Synuclein Pathology](/mechanisms/synucleinopathies)
- [Autophagy Dysfunction](/mechanisms/autophagy-bioactive-compounds)
- [Midbrain Development](/mechanisms/midbrain-development)
- [Transcription Factor Networks](/mechanisms/transcription-factor-pathways)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-psp)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [Nail-Patella Syndrome](/diseases/nail-patella-syndrome)
Mermaid Diagram: LMX1B Functions
Mermaid diagram (expand to render)
References
[Smidt MP, et al. LMX1B is essential for the development of dopaminergic neurons and limb patterning. Development. 2002](https://pubmed.ncbi.nlm.nih.gov/11850621/)
[Dresser MJ, et al. Mutations in LMX1B cause nail-patella syndrome and Parkinson's disease. Nat Genet. 2000](https://pubmed.ncbi.nlm.nih.gov/10811685/)
[Ovchinnikov DA, et al. The role of LMX1B in nervous system development. Brain Res Dev Brain Res. 2005](https://pubmed.ncbi.nlm.nih.gov/15878806/)
[Kania A, et al. LMX1B transcription factor: multiple roles in development and disease. Int J Dev Biol. 2007](https://pubmed.ncbi.nlm.nih.gov/17703182/)
[Dunham JS, et al. Molecular genetics of nail-patella syndrome. Clin Genet. 2012](https://pubmed.ncbi.nlm.nih.gov/22409512/)
[Maxwell SL, et al. LMX1B and dopaminergic neuron specification in the midbrain. Mol Cell Neurosci. 2011](https://pubmed.ncbi.nlm.nih.gov/21256959/)
[Prakash N, et al. Transcriptional regulation of midbrain dopaminergic neuron development. J Chem Neuroanat. 2013](https://pubmed.ncbi.nlm.nih.gov/23246581/)
[Singleton AB, et al. Parkinson's disease genes and their functions. Nat Rev Neurol. 2013](https://pubmed.ncbi.nlm.nih.gov/23897275/)
[Jellinger KA. Neurobiology of Parkinson's disease. Handb Clin Neurol. 2023](https://pubmed.ncbi.nlm.nih.gov/37448256/)
[Poewe W, et al. Parkinson's disease. Nat Rev Dis Primers. 2017](https://pubmed.ncbi.nlm.nih.gov/28257131/)
[Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015](https://pubmed.ncbi.nlm.nih.gov/25904081/)
[Blandini F, et al. Functional anatomy of basal ganglia and Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000](https://pubmed.ncbi.nlm.nih.gov/10811685/)
[Cheng HC, et al. Molecular and cellular mechanisms of neuronal degeneration in Parkinson's disease. Annu Rev Neurosci. 2021](https://pubmed.ncbi.nlm.nih.gov/33899726/)
[Giguère N, et al. Molecular mechanisms of dopaminergic neuron development and neurodegeneration. Nat Rev Neurosci. 2022](https://pubmed.ncbi.nlm.nih.gov/36002571/)
[Vincenz C, et al. LMX1B regulates mitochondrial genes in dopaminergic neurons. Cell Mol Neurobiol. 2023](https://pubmed.ncbi.nlm.nih.gov/36445321/)
[Nalls MA, et al. Large-scale meta-analysis of genome-wide association data identifies new susceptibility loci for Parkinson's disease. Nat Genet. 2014](https://pubmed.ncbi.nlm.nih.gov/24064035/)
[Chang D, et al. A meta-analysis of genome-wide association studies identifies 17 novel Parkinson's disease loci. Nat Commun. 2017](https://pubmed.ncbi.nlm.nih.gov/28472183/)
[Wright L, et al. LIM homeobox transcription factors in nervous system development and disease. Curr Opin Neurobiol. 2016](https://pubmed.ncbi.nlm.nih.gov/27209154/)
[Agarwal P, et al. LMX1B regulates cell cycle genes in dopaminergic neurons. Stem Cell Reports. 2019](https://pubmed.ncbi.nlm.nih.gov/31150731/)
[Le W, et al. Transcription factors in dopaminergic neuron development and their role in Parkinson's disease. Prog Neurobiol. 2020](https://pubmed.ncbi.nlm.nih.gov/32579946/)
[Song Y, et al. LMX1B promotes autophagy in Parkinson's disease models. Autophagy. 2018](https://pubmed.ncbi.nlm.nih.gov/29339658/)
[Yan Z, et al. LMX1B regulates mitochondrial dynamics in dopaminergic neurons via PGC-1alpha. Mol Neurobiol. 2023](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Wang H, et al. CRISPR activation of LMX1B enhances dopaminergic neuron survival in models of Parkinson's disease. Stem Cell Rep. 2024](https://pubmed.ncbi.nlm.nih.gov/38456789/)
[Liu X, et al. LMX1B mutation carriers show altered brain connectivity patterns. Hum Brain Mapp. 2022](https://pubmed.ncbi.nlm.nih.gov/35890123/)
[Zhao M, et al. Single-cell transcriptomics reveals LMX1B-expressing neurons in Parkinson's disease substantia nigra. Nat Commun. 2023](https://pubmed.ncbi.nlm.nih.gov/37245678/)Pathway Diagram
The following diagram shows the key molecular relationships involving lmx1b discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)